Natera (NTRA) Q4 2025 earnings review
MRD Hypergrowth Meets Remarkable Operating Leverage
Natera delivered a phenomenal close to FY2025, beating previous revenue expectations with $665.5M in Q4 (+40% YoY). The growth engine is Signatera, which saw clinical molecular residual disease (MRD) test volumes accelerate by a staggering 56% YoY to 225,000 units. More importantly, the business model has officially inflected: Natera generated $107.6M in positive cash flow for the year and achieved a 66.9% gross margin in Q4. Looking to 2026, management expects to hold SG&A completely flat while growing pro forma revenue by ~25%, signaling massive operating leverage. However, heavily scaled R&D investments and conservative gross margin guidance (63-65%) indicate that the cost of chasing the next leg of growth remains steep.
🐂 Bull Case
Signatera sequential unit growth continues to accelerate (+22.8K in Q4 vs +21.5K in Q3), solidifying Natera's position as the dominant player in the underpenetrated MRD space.
Guidance for 2026 holds SG&A flat at ~$1.17B despite projecting ~25% pro forma revenue growth. The 'slingshot effect' from 2025's commercial hires is kicking in, guaranteeing high flow-through to the bottom line.
🐻 Bear Case
R&D expense is guided to surge 28% to an $800M midpoint in 2026 as the company funds its high-risk FIND-CRC early cancer detection study and expands AI initiatives.
FY2025 revenue was heavily subsidized by $194M in prior-period true-ups. While management achieved a 66.9% gross margin in Q4, guiding down to 63-65% for 2026 reveals that base pricing remains challenged.
⚖️ Verdict: 🟢
Bullish. Natera is successfully crossing the chasm from cash-burning growth stock to a cash-generating, highly leveraged market leader. While R&D spending is aggressive, it is directed at expanding an already imposing clinical moat.
Key Themes
Unprecedented SG&A Leverage
Accelerating. Natera has clearly reached an inflection point in its commercial scalability. After increasing SG&A by 40% in FY25 to rapidly expand its oncology sales force, management is guiding for essentially flat SG&A in 2026 ($1.125B - $1.225B) against $2.66B in expected revenue. This proves the company can successfully scale volumes without a 1-to-1 increase in headcount.
Expanding Clinical Data Moat
Stable. Natera continues to weaponize data to box out competitors. Key readouts from IMvigor011 (bladder cancer), EXPAND (single-gene NIPT), and PEDAL (organ transplant) have repeatedly demonstrated clinical utility and predictive superiority. Management is actively turning this 'Level 1A evidence' into guideline inclusions and expanded MolDX coverage, directly driving higher ASPs.
Macro Tailwind: State-Level Biomarker Mandates
Accelerating. A key macro driver shielding Natera from commercial payer stinginess is the continued rollout of state-level biomarker testing laws. Management has noted these mandates force large national payers to cover tests in specific jurisdictions, creating a structural 'drumbeat' that incrementally lifts the blended Average Selling Price (ASP) without requiring national policy changes.
Guidance Contradicts Margin Exuberance
Management touted that Q4 gross margins came in 'well ahead of our expectations' at an impressive 66.9%. However, 2026 guidance projects a reversion back down to 63-65%. This specific data point directly contradicts the narrative of unchecked margin expansion, highlighting that Q4's peak benefited from ~2% in one-time revenue true-ups and that conservative ASPs and higher early-phase sequencing costs will persistently drag on the 2026 run rate.
R&D Expense Explosion
Accelerating. While SG&A is flattening, R&D is skyrocketing. Natera is guiding R&D to a midpoint of $800M in FY26, a massive 28% YoY jump from $624M. This capital is being poured into the high-risk, FDA-enabling FIND-CRC study for early cancer detection—a notoriously difficult and fiercely competitive market that won't see pivotal readouts until 2027.
ADLT Price Resets Threaten ASPs
Stable. While Natera aggressively pursues new tumor type coverage, a structural headwind looms. CFO Mike Brophy previously warned of a scheduled ADLT (Advanced Diagnostic Laboratory Test) pricing reset for Signatera. This regulatory mechanism introduces mandatory pricing reassessments based on commercial payer rates, acting as a direct decelerating force against ASP expansion in 2026.
Ultra-Sensitive Innovation: Signatera Genome
Natera has successfully rolled out Signatera Genome, utilizing proprietary 'Phased Variants' technology to detect tumor DNA down to 1 part per 10 million. This technological leap provides a highly compelling surveillance tool for biopharma partners and acts as a defensive moat against newer competitors who attempt to market higher analytical sensitivity.
Other KPIs
Accelerating. Up 51.6% from 528,200 in FY24. Q4 alone processed 233,300 tests (+54.7% YoY), underscoring that broader market penetration is not slowing down despite the law of large numbers beginning to apply to the base.
Reversing. Natera has officially transitioned from structurally burning cash to generating it. This metric combines operating cash flow, routine cap-ex, and minor financing, giving management a self-funding mechanism for its aggressive $800M R&D pipeline without tapping the equity markets.
Accelerating. A vast improvement from the $(64.7) million operating loss in Q4 2024. As revenue scales past fixed lab costs and SG&A leverage takes effect, the company is rapidly closing the gap to GAAP operating profitability.
Guidance
Accelerating. The midpoint of $2.66B implies 15.3% GAAP growth over FY25's $2.31B. However, because FY25 included $194M in backward-looking revenue true-ups, management notes this actually implies a blistering ~25% pro forma growth rate on the underlying base business.
Decelerating vs Q4. Management is guiding for margins to step down from the 66.9% achieved in Q4. This reflects the exclusion of unpredictable revenue true-ups from the forecast and inherently conservative ASP assumptions as Signatera expands into lower-reimbursed tumor types.
Stable. The $1.175B midpoint represents 0% YoY growth compared to the $1.177B spent in FY25. Management expects to fully harvest the 'slingshot effect' from 2025's commercial sales force expansion, driving massive margin flow-through.
Accelerating. The $800M midpoint implies a heavy 28% YoY increase. This massive spend is explicitly earmarked to complete enrollment in the FIND study for early cancer detection and to further build out proprietary AI foundation models.
Key Questions
Gross Margin Bridge and Reversion
With Q4 organic gross margins (excluding true-ups) expanding roughly 240 bps sequentially to hit nearly 65%, why does the 2026 guidance of 63-65% imply a stagnation or step backward? What specific COGS or ASP headwinds are you bracing for?
AI Monetization Timeline
You've previously highlighted a potential $200M operational savings from AI and deep learning across revenue cycle and lab operations. How much of this efficiency is actively baked into your flat 2026 SG&A guidance versus potential upside in future years?
M&A vs Organic Capacity
With over $1.07 billion in cash and investments and structural cash flow positivity, your balance sheet is a fortress. As R&D spend peaks with the FIND study, will excess capital be deployed toward share repurchases, or are you actively assessing M&A to acquire complementary tech?